anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Despite a lack of evidence that intentional weight loss reduces the risk of postoperative complications, adults with obesity are commonly asked to lose weight before elective surgery. We hypothesized that patients undertaking dietitian-led preoperative, very low calorie diet treatment could reduce perioperative surgery risks, as per validated risk scoring systems. The purpose of this study was to measure the impact of a dietitian-led preoperative very low calorie diet clinic on the American Society of Anesthesiologists physical status scores and National Surgical Quality Improvement Program Surgical Risk Calculator scores for patients with obesity awaiting non-bariatric elective surgery.
METHODS: This retrospective cohort study included patients referred to the preoperative dietitian-led very low calorie diet clinic before elective surgical procedures over a 2-year-9-month period. The dietitian prescribed individualized, very low calorie diet-based treatment. Primary outcomes were changes in the American Society of Anesthesiologists and Surgical Risk Calculator scores from pretreatment until surgery.
RESULTS: A total of 141 eligible participants (48 ± 13.4 years, 76% women, body mass index 41.7 ± 6.3 kg/m2) demonstrated clinically significant weight loss (mean 7.1 ± 6.1kg, 5.2% body weight, P < .001). Median treatment duration was 13 weeks (interquartile range 6.2-19.2 weeks). Five participants (3.5%) avoided surgery due to weight loss-related improvements in their condition. American Society of Anesthesiologists scores improved for 16% (n = 22/141) of participants. Overall, the median surgical risk calculator estimated risk of 'serious' and 'any' postoperative complication reduced from 4.8% to 3.9% (P < .001) and 6% to 5.1% (P < .001), respectively. Reduction in all Surgical Risk Calculator scores occurred, including surgical site infection, re-admission, and cardiac events (P < .05).
CONCLUSION: The dietitian-led preoperative, very low calorie diet clinic improved American Society of Anesthesiologists and Surgical Risk Calculator scores for non-bariatric elective surgery patients with obesity. Randomized controlled trials comparing this approach with a control group are warranted.
ESAU therapists will be given standard, paper-based facilitation resources for STAND and will receive 4 hours of training on how to navigate these materials and self-assess fidelity. ESAU therapists will also be trained how to upload recordings into Care4 and complete self-assessments for each session. Supervisors will be given access to these data and recordings once uploaded (but not Lyssn scores or electronic facilitation resources).
The invention relates to a traditional Chinese herbal composition for specifically treating depression. The traditional Chinese herbal composition comprises the following raw materials: wolfberry, angelica sinensis, honeysuckle stems, arillus longan, cassia twig, dry ginger, rhizoma polygonati, dandelion, scutellaria baicalensis, rhizoma anemarrhenae, polygala tenuifolia, liquorice, fructus schisandrae, root of rehmannia, flos caryophylli and radix polygonati officinalis. The traditional Chinese herbal composition has a good effect for treating the depression. The main clinic characteristic of the depression is remarkable and lasting depressing mood. A majority of the cases are likely to recurrent, and the pathogenesis is not clear. The pathogenesis of the depression is researched on the aspect of the traditional Chinese medicine, and the traditional Chinese herbal composition for treating the depression is found from the practice. The pathological nature of the depression is asthenic disease, and the depression is caused by long-term excessive application of eyes and brain, consumption of blood and injury of internal organ function. The traditional Chinese herbal composition has a unique curative effect on the depression caused by the asthenic injury of the consumption of the blood. Not only can the syndrome be eliminated, but also the body can be comprehensively conditioned according to the pathogenesis, the disease can be treated, and the creative condition and recurrence can be avoided.
Ciprofloxacin is eliminated primarily by renal excretion; however, the drug is also metabolized and partially cleared through the biliary system of the liver and through the intestine. These alternate pathways of drug elimination appear to compensate for the reduced renal excretion in patients with renal impairment. No dosage adjustment is required for patients with uncomplicated urinary tract infections receiving 500 mg ciprofloxacin extended-release tablets. In patients with complicated urinary tract infections and acute uncomplicated pyelonephritis, who have a creatinine clearance of < 30 mL/min, the dose of ciprofloxacin extended-release tablets should be reduced from 1000 mg to 500 mg daily. For patients on hemodialysis or peritoneal dialysis, administer ciprofloxacin extended-release tablets after the dialysis procedure is completed. (See CLINICAL PHARMACOLOGY, Special Populations, and PRECAUTIONS, Geriatric Use.)
The invention relates to a drug and a medical device for remedying the calcaneodynia. The drug for remedying the calcaneodynia consists of the following components (which are calculated according to the weight unit) of 4 to 6 portion of Chinese clematis, 2 to 3 portion of Szechwan lovage rhizome and 2 to 3 portion of borneol. An insole for remedying the calcaneodynia is provided with an insole cover and traditional Chinese medical mats. The insole cover is provided with a bottom part and lateral wing parts, which are placed above the bottom part, and the bottom part and the lateral wing parts are all provided with interlayers, which are mutually communicated. The traditional Chinese medical mats are placed inside the interlayer of the bottom part and the interlayers of the lateral wing parts. The invention adopts the totally novel method to remedy the calcaneocynia, which mainly consists of two parts of a part of traditional Chinese medicine, which can take effect of activating blood circulation and dredging channels for alleviating pain and another part of the special insole for fixing the medicine to promote the medicine being completely absorbed by the affected part. Compared with medical fumigation and washing and medical soaking, the acting time of the insole is prolonged greatly, because the insole can be put inside a shoe or is directly tied at the heel after the shoe is put off, and the insole can continuously remedy for a whole day of twenty four hours. The insole has the characteristics of being simple for operating, being convenient for using, being comfortable for wearing, being economical, practical, safe and reliable.
FIELD: medicine. SUBSTANCE: invention relates to a liquid that can destroy superoxide anion-radicals which are inducers of different diseases. Crude water containing at least ions of sodium, potassium, magnesium and calcium is fed in cathode chamber where electrolysis of crude water is carried out for 0.5-5 s by current passing through cathode and anode electrode at the range 0.16-3.2 mA/cm 2  as measured for two electrodes and a single diaphragm. By this method water is obtained that can be used for conservative treatment. This water has a redox potential value (at the range) at least -150 mV if measurement is carried out by platinum electrode using. This water can remove superoxide anion-radicals from patient blood. EFFECT: improved method of medicinal liquid preparing. 17 cl, 8 dwg, 3 tbl
The present invention relates generally to the field of peptides and other small molecules (i.e. peptide mimetics) as pharmaceutical and/or therapeutic agents, and to methods for identification and design of peptides and peptide mimetics having desired functional activities. Specifically, peptides and other small molecules derived from regions of interacting intracellular signaling proteins are provided. More specifically, peptides and other small molecules derived from regions of the Gβ subunit of heterotrimeric GTP binding proteins are provided. Such molecules include specific agonists and antagonists of Gβ downstream effectors, including adenylyl cyclase and phospholipase C. Such molecules are targeted to predicted regions of interaction between intracellular signaling proteins and tested for activity in functional assays using methods of the invention. One major advantage of the invention is the incorporation of three-dimensional structural information in models used for predicting interaction surfaces between intracellular proteins. Another major advantage is the ability to distinguish, within a predicted interaction surface, a signal transfer region from a general binding domain. Resolution of such signal transfer regions from general binding domains is useful for prediction and validation of pharmacologic and therapeutic agonists and antagonists.
Preoperative fasting has always been problematic in preoperative patients because of the pulmonary aspiration hazard and discomfort of prolonged fasting. Although stomach scintigraphy has been accepted as a gold standard for imaging method of evaluating gastric content; recently, ultrasound is being a simple, efficient, available and non invasive alternative. Preoperative fasting is especially difficult in elderly because of comorbidities, dehydration, drug therapies. Therefore, in this study gastric emptying time will be identified after a standard Turkish breakfast in over 65 years old Turkish population to clarify fasting time, measuring antral cross section area (CSA) by using non invasive ultrasound for the first time. Ultrasound assessments on volunteers will be made both in the supine position and right lateral decubitus (RLD) from the epigastric area by using a convex probe. After visualization of gastric antrum according to landmarks such as abdominal aorta, superior mesenteric artery and the left lobe of liver; antrum will measured in two sagittal planes: craniocaudal (CC) and anteroposterior(AP) diameters. Gastric emptying time will be identify by real time usg done by 1 hour intervals.This is the first study with ultrasound evaluation of gastric emptying time in Turkish population after a traditional Turkish breakfast.
A process for preparing optical-purity adrenin beta-excitomotors by combination-disconnection method is disclosed. On the basis of combination chemistry, the recemic beta-excitomotor is used as raw material. The tartaric and one or more of tis derivatives are used for disconnection to obtain two beta-excitamotors with different configurations, e. e. value greater than 99% and the output rate higher than 70%. The the inorganic acid's salt of optically active beta excitomotors with optical purity greater than 99% e.e. value and chemical purity higher than 99% is also obtained. Its advantages include simple operation, less by-reaction, and high effect.
BACKGROUND: Sleeve gastrectomy is the most frequently performed bariatric surgery, however several patients did not achieve satisfactory weight loss or suffer of weight regain. The SADI-S has been proposed as an acceptable revision surgery with good results and low complications rate. Our objective is to present the first case of SADI-S performed in the Mexican Institute of Social Security as surgical revision after sleeve gastrectomy for weight regain.
CLINIC CASE: A 50-year-old man presented with a history of type 3 obesity (weight 167 kg, BMI 48.8), hypertension, dyslipidemia, and obstructive sleep apnea, summited to sleeve gastrectomy on 2019 with weight regain of 49.5 % of excess weight lost in 2 years (weight 156 kg, BMI 45.6, %EWL 13.5 %), so we decided to perform a SADI, with preoperative weight 138 kg and BMI 40.3 kg/m2. The surgery occurred without complications, and he was discharged on postoperative day 2. At six months of follow-up continue with satisfactory weight loss (% EWL 52%), comorbidities remission, asymptomatic and laboratory tests without data of malnutrition or anemia.
CONCLUSIONS: The SADI-S seems to be the best option for revisional surgery after sleeve gastrectomy for unsatisfied weight loss or weight regain, so it was the procedure of choice in our case with satisfactory outcomes. We consider the SADI-S as a secure and efficient option for patients with resistance to weight loss.
BACKGROUND: Postoperative recurrence is a vital reason for poor 5-year overall survival in hepatocellular carcinoma (HCC) patients. The ADV score is considered a parameter that can quantify HCC aggressiveness. This study aimed to identify HCC patients at high-risk of recurrence early using the ADV score.
METHODS: The medical data of consecutive HCC patients undergoing hepatectomy from The First Affiliated Hospital of Nanjing Medical University (TFAHNJMU) and Nanjing Drum Tower Hospital (NJDTH) were retrospectively reviewed. Based on the status of microvascular invasion and the Edmondson-Steiner grade, HCC patients were divided into three groups: low-risk group (group 1: no risk factor exists), medium-risk group (group 2: one risk factor exists), and high-risk group (group 3: coexistence of two risk factors). In the training cohort (TFAHNJMU), the R package nnet was used to establish a multi-categorical unordered logistic regression model based on the ADV score to predict three risk groups. The Welch's T-test was used to compare differences in clinical variables in three predicted risk groups. NJDTH served as an external validation center. At last, the confusion matrix was developed using the R package caret to evaluate the diagnostic performance of the model.
RESULTS: 350 and 405 patients from TFAHNJMU and NJDTH were included. HCC patients in different risk groups had significantly different liver function and inflammation levels. Density maps demonstrated that the ADV score could best differentiate between the three risk groups. The probability curve was plotted according to the predicted results of the multi-categorical unordered logistic regression model, and the best cut-off values of the ADV score were as follows: low-risk ≤ 3.4 log, 3.4 log < medium-risk ≤ 5.7 log, and high-risk > 5.7 log. The sensitivities of the ADV score predicting the high-risk group (group 3) were 70.2% (99/141) and 78.8% (63/80) in the training and external validation cohort, respectively.
CONCLUSION: The ADV score might become a valuable marker for screening patients at high-risk of HCC recurrence with a cut-off value of 5.7 log, which might help surgeons, pathologists, and HCC patients make appropriate clinical decisions.
Wilms tumor, the most common pediatric kidney cancer, accounts for 5% of childhood cancers and is classified by stage and histological subtype. Despite high survival rates (80-85%), approximately 15% of patients experience relapse, reducing survival to around 50%. Epigenetic changes, particularly DNA methylation, play a critical role in Wilms tumor pathogenesis. This study investigates the prognostic potential of DNA methylation in stage I and II patients with favorable histology, aiming to identify early relapse biomarkers. Genome-wide methylation was assessed using methylation microarrays in tumor tissues from relapsed patients (n = 9) and those with complete responses (n = 9), alongside normal tissues (n = 3 each). Differentially methylated probes and regions were analyzed, with additional ROC and survival analyses. Real-time PCR was used to measure IGF2 and INS-IGF2 gene expression. The analysis revealed hypomethylation in intergenic regions in remission patients, identifying 14 differentially methylated positions as potential biomarkers. Increased INS-IGF2 expression was associated with relapse, suggesting its role in disease progression. While the study concentrated on stages I and II patients, where relapse rates are lower, this focus inherently led to a smaller sample size. Despite this, the findings provide valuable insights into the potential role of DNA methylation markers for monitoring disease progression and guiding personalized treatment in Wilms tumor patients.
BACKGROUND: Multiple factors contribute to recurrences in differentiated thyroid cancers (DTC). Though the nodal size and number of positive nodes along with the presence of extranodal extension (ENE) have been mentioned in the present ATA risk stratification, the weightage given for ENE seems inadequate compared to the former two.
METHODOLOGY: Factors predicting recurrences were analysed in this retrospective study of patients with DTC operated in a tertiary care centre. Based on our findings, we propose a modification in the present risk stratification. We have done so by comparing with existing risk stratification for fit and discrimination of this system.
RESULTS: Out of 1428 patients, 859 (60.2%) patients had pathological nodal metastases (pN +) with ENE being present in 26.8% of these. The recurrence rate was 6.4% (92 patients). Recurrence rates in patients with ≤ 5 nodes without ENE, > 5 nodes without ENE, ≤ 5 nodes with ENE and > 5 nodes with ENE were 2.7%, 1.3%, 8.3% and 10.3%, respectively. Recurrence rates in patients with 0.2-3 cm without ENE, 0.2-3 cm with ENE and > 3 cm with/without ENE were 1.8%, 8.5% and 13.4%, respectively. A modified risk stratification incorporating ENE and excluding the number of metastatic nodes was proposed. The modified risk stratification had a better fit than the present system in terms of higher C index and lower AIC.
CONCLUSIONS: Extranodal extension in differentiated thyroid cancer had the maximum influence on recurrence risk (recurrence-free survival) in our cohort. The prognostic impact of ENE supersedes the number of positive nodes in the risk of recurrence.
PROBLEM TO BE SOLVED: To obtain the subject new antagonist inhibiting inflow of calcium to cell by using an extract of salivary gland of shrew as an active ingredient. SOLUTION: This antagonist contains an extract of salivary gland of shrew as an active ingredient. An insectivore such as Sorex unguiculatus Dobson or Sorex shinto saevus Thomas is exemplified as the shrew. A lower alcohol such as ethanol or ketone such as acetone is exemplified as organic solvent used for extraction. When an auxiliary for production such as excipient and disintegrator is used, formulating amount of an extract of salivary gland is preferably 0.2-10wt.%. The daily dose of the extract is preferably 1-1,000mg when an adult is treated as the concentrate of the extract and the extract is preferably administered in 2-3 divided portions.
The purpose of the study is to compare standard enteral nutrition regimen with the enteral nutrition regimen supplemented with whey protein in severe neurological disease patients and to observe nutritional indicators improvement in these patients. A total of 116 subjects will be included. Counting process is as follows: referring available literature and the mean value of serum albumin in patients on the 14th day of our preliminary tests, and the difference test is used to compare the mean values of two independent samples. The ratio of the experimental group and control group is 1:1. It was assumed that the serum albumin level in the experimental group was higher than that in the control group. A single end is taken, α=0.05, 1-β=0.80, experimental group patients serum albumin（Χ±S）=37.9±5.1, the control group serum albumin（Χ±S）=35.6±4.8, so the total sample size was 116.It was estimated that 116 patients were enrolled consecutively, which were divided into experimental group and control group by computer generated random number table. Patients in both groups received enteral nutrition therapy with continuous tube feeding for 14 days. According to the nutritional treatment requirements of critically ill patients in the Asia-Pacific region in 2016, patients with severe acute stress were given energy demand for 25\~30kcal/kg/d, protein demand for 1.2\~2g/kg/d and other standardized clinical treatments. Control group nutrition program: standardized enteral nutrition preparation only. Experimental group nutrition program: whey protein powder was added on the basis of standardized enteral nutrition preparation. According to the body weight of the patients, different enteral nutritional preparations and dose adjustments were selected to ensure that the calorie and protein intake of the two groups of patients met the above nutritional treatment requirements.Primary endpoint: serum albumin level at 14 days of enteral nutrition. Secondary end points: 1. APACHE II, GCS and other clinical scores at 14 days; 2. total serum protein, proalbumin, hemoglobin and other nutritional indicators; 3. the number and ratio of white blood cells, neutrophils, c-reactive protein, interleukin-6, procalcitonin, absolute count of T lymphocyte subsets, immunoglobulin and other inflammatory indicators at 14 days; 4. the number of cases of gastrointestinal complications such as gastric retention, vomiting, diarrhea, abdominal distention, constipation and gastrointestinal bleeding during the 14 days of enteral nutrition; 5. the number of patients with serum albumin \< 30g/L within 14 days after admission.
AÂ method of reducing the respiratory depressant effect associated with diamorphine (diacetylmorphine, morphine diacetate or heroin) administration, wherein the method comprises administering intranasally a single dose pharmaceutical composition comprising (a) lyophilised diamorphine or a pharmaceutically acceptable salt thereof; and (b) a diluent for reconstitution comprising a preservative, a chelating agent, one or more osmolarity modifiers and a pH modifier. Preferably the osmolarity modifiers are selected from the group including sodium chloride, potassium chloride, glycerol (glycerine), trehalose, mannitol, sorbitol, dextrose, lactose and arginine. The preservatives may be selected from m-cresol, phenol, alcohol, benzyl alcohol, methyl-, ethyl-, propyl- and butyl-paraben, thiomersal, chlorobutanol, benalkonium chloride or combination thereof. Preferably the chelating agent is edetic acid and its salts, including sodium edentate or disodium dentate. The pH modifier may be selected from sodium hydroxide, hydrochloric acid and buffers such as phosphate, acetate, carbonate, citrate, glutamate and prolamine. The formulation is useful in the treatment of pain. A kit for the preparation of a multi-dose pharmaceutical composition of a nasal analgesic in the form of a nasal spray comprising a bottle containing a lyophilised nasal analgesic, a tube containing a diluent for reconstitution, modified nasal pump, one or more disposable nasal tips and instructions for assembly is also outlined.
Gastric cancer is one of the most common malignancies in China with incidence and mortality both ranking the 2nd among malignancies in China. Unfortunately, over 70% of gastric cancer patients in China were diagnosed in advanced stage, and more than 80% of adenocarcinoma of esophagogastric junction(AEG) were advanced stage. Locally advanced AEG (cT3-4aN+M0) could be cured by multi-disciplinary therapies including surgery, chemotherapy and radiotherapy. As proved, Neoadjuvant chemotherapy can downstage T and N stage, increase the resectability of tumor, and finally improve the long-term survival in AEG patients. However, the therapeutic effects remain unsatisfactory. PD-1 antibody has demonstrated its efficacy in metastatic AEG and has been proved to be effective in neoadjuvant setting in lung cancer and melanoma. Combination of perioperative PD-1 antibody and chemotherapy for locally advanced could be a novel therapy to increase response rate and resectability and reduce recurrence rate. Sinitilimab in this study is an anti-PD-1 monoclonal antibody for injection which has been approved for lymphoma. This study is a multi-center, open-label, randomized phase II clinical trial to evaluate tolerability, safety and efficacy of sinitilimab in combination with perioperative chemotherapy（SOX: oxaliplatin plus S-1） in locally advanced AEG.